A2780ADR Cell Line human

93112520, human ovary, Epithelial

• Synonym(s): A2780-ADR Cells
• UNSPSC Code: 41106514

Properties

• product name: A2780ADR Cell Line human, 93112520
• biological source: human ovary
• description: Human Caucasian ovarian carcinoma
• growth mode: Adherent
• karyotype: Not specified
• morphology: Epithelial
• products: Not specified
• receptors: Not specified
• technique(s): cell culture | mammalian: suitable
• relevant disease(s): cancer
• shipped in: dry ice
• storage temp.: −196°C

Description

Cell Line Origin

Human Caucasian ovarian carcinoma

Cell Line Description

The adriamycin-resistant cell line A2780ADR has been developed by exposure of the parent A2780 cell line (Sigma catalogue no. 93112519) to adriamycin. A2780ADR is cross-resistant to melphalan and vinblastine. To retain resistance adriamycin has to be added to the media. The cells grow as a monolayer and in suspension in spinner cultures and are tumourigenic in immune deficient mice. Together with the cisplatin-resistant variant A2780cis these lines only differ in their exposure to a single drug and should facilitate the search for molecular changes responsible for the expression of pleiotropic drug resistance in human ovarian cancer.

Application

Study of drug transport, toxicity testing, drug resistance cancer studies

DNA Profile

STR-PCR Data: Amelogenin: X
CSF1PO: 10,11
D13S317: 13
D16S539: 11,14
D5S818: 11,12
D7S820: 10
THO1: 6
TPOX: 8,9
vWA: 15,16

Culture Medium

RPMI 1640 + 2mM Glutamine + 10% Foetal Bovine Serum (FBS); treatment with 10E-7 M adriamycin at least once a week.

Subculture Routine

Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 5x1,000 to 2x10,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C. Recommendation: culture cells without drug after resuscitation until growth has been fully established.

Other Notes

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

Disclaimer

This cell line has special release conditions: Commercial organisations are required to complete the ′Cell Line Release Authorisation for Research Use in Commercial Organisations′ release conditions form.